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Abstract 
IDENTIFICATION OF THE RNA CIS-ELEMENTS THAT INTERACT WITH SRP30A 
TO REGULATE THE ALTERNATIVE SPLICING OF CASPASE 9 PRE-MRNA 
By Prabhat Mukerjee, M.S.. 
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
Virginia Commonwealth University, 2005 
Major Director: Dr. Charles E. Chalfant, Ph.D. 
Assistant Professor, Biochemistry 
Studies have shown that the alternative splicing of caspase 9 and the phospho- 
status of SR proteins, a conserved family of splicing factors, are regulated by 
chemotherapy and de novo ceramide via the action of protein phosphatase-1 (PP1). Two 
RNA splice variants are derived from the caspase 9 gene, pro-apoptotic caspase 9a and 
anti-apoptotic caspase 9b, via alternative splicing by either the inclusion or exclusion of an 
exon 3, 4, 5 ,  and 6 cassette. In this study, the link between SR proteins and the alternative 
splicing of caspase 9 was established. Sequence analysis of the exon 3, 4, 5 ,  and 6 cassette 
of the caspase 9 gene identified five possible high affinity sequences for interaction with 
vii 
. . . 
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the SR protein, SRp30a, a well-established regulator of exon inclusion/exclusion. 
Replacement mutagenesis identified purine-rich sequences between exons 4 and 5 and 
wthin exon 6 as important for binding SRp30a and required for expression of the caspase 
9a splice variant. In vitro binding assays coupled with competitor studies demonstrated 
specific binding of RNA trans-acting proteins and SRp30a with these sequences. 
Furthermore, SDS-PAGE analysis of cross-linked RNA trans-acting factors with these 
possible RNA cis-elements revealed the specific binding of an approximate 66, 56, 45, and 
38 kDa proteinlprotein complex to these sequences. A previous application of RNAi 
technology to downregulate SRp30a in A549 lung adenocarcinoma cells induced an 
approximately 75% decrease in SRp30a expression and induced a dramatic change in the 
ratio of caspase 9alcaspase 9b. Therefore, these studies have identified SRp30a as a major 
regulator of the alternative splicing of caspase 9 directly linking de novo ceramide 
generation, PP1, and SRp30a as the signal transduction pathway regulating the expression 
of caspase 9. 
CHAPTER 1 Introduction 
Overview of Apoptosis and the roles of Caspase 9a and Caspase 9b 
Apoptosis (used here interchangeably with programmed cell death) is a mechanism 
(or group of mechanisms) by which cells execute endogenous programs of cell death, often 
in response to adverse external or internal signals or sources of injury. In the case of 
cancer, interference with this system of programmed cell death can lead to expansion of 
deleterious cells. Apoptosis is regulated by multiple factors through complex mechanisms. 
It has become well established that many inducers of apoptosis (e.g. chemotherapy) 
activate caspases, and that the activation of these cysteine proteases is perhaps the point of 
irreversible commitment to the onset of apoptosis. In normal, healthy cells, a protein 
known as cytochrome c is sequestered between the inner and outer membranes of 
mitochondria (1). In the presence of apoptotic death inducing stimuli, such as 
chemotherapeutics or oxygen free radicals, monomers of a protein known as Bax migrate 
from the cytosol to the outer membranes of the mitochondria, homodimerize, and form a 
channel permitting ions to flow into the intermembranous space (1). This ion flux, through 
an unknown mechanism, triggers cytochrome c to be released into the cytosol where it 
binds to an adaptor protein known as Apaf- 1. Apaf- 1 then binds pro-caspase 9 and using 
the energy from the hydrolysis of ATP, pro-caspase 9 autoproteolyzes into the active 
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caspase 9 (2). The trimeric complex of pro-caspase 9 with cytochrome c and Apaf-1, 
known as the apoptosome, is shown in Figure 1. Caspase 9 is a member of the caspase 
family of proteases that functions as an initiator caspase. Active caspase 9 cleaves pro- 
caspase 3 into the active caspase 3 which cleaves additional substrates and leads to cell 
death (2). 
Caspase 9 has two antagonistic isoforms in programmed cell death: the pro- 
apoptotic caspase 9a and the pro-survival caspase 9b as shown in Figure 2. The caspase 9 
gene is composed of eight introns and nine exons. Of these nine exons, the exon 3, 4, 5, 
and 6 cassette encodes for the catalytic domain of caspase 9. If this cassette is included, the 
caspase 9a splice variant is produced and if it is excluded, the caspase 9b splice variant is 
produced. The caspase 9b variant lacks the catalytic protease domain and acts as a 
dominant negative to the caspase 9a splice variant such that the translated caspase 9b 
competes for Apaf-1 binding and also heterodimerizes with caspase 9a preventing it from 
being activated. In this way, caspase 9b acts as an anti-apoptotic factor. This suggests that 
alternative splicing, such as the alternative exon inclusion of caspase 9, may be an 
important mechanism in the regulation of cell fate. 
wr 
rtpoptotic 
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Figure 1. Overview of the role of Caspase 9 in apoptosis. 
The activation of caspase 9 occurs by pro-caspase 9 forming a trimeric complex known as 
the apoptosome with two other proteins, apaf-1 and cytochrome c. This trimeric complex 
utilizes the energy released from the hydrolysis of ATP to cleave pro-caspase 9 into an 
activated caspase 9 and initiating the apoptotic cascade. 
Caspase 9b mRNA 
(Anti-Apoptotic) 
Cassette Exclusion 
Caspase 9 Pre-mRNA 
1 Cassette Inclusion Caspase 9a mRNA (Pro-Apoptotic) 
Figure 2. Overview of Caspase 9 structure and its splice 
variants. Two splice variants can be formed from caspase 9 pre-mRNA, caspase 9a and 
caspase 9b. Determination of which splice variant is produced depends on whether the exon 3,4,5, 
6 cassette is included or excluded. When the exon 3,4, 5, 6 cassette is included during the splicing 
process, the pro-apoptotic caspase 9a rnRNA is expressed. When the exon 3, 4, 5, 6 cassette is 
excluded during the splicing process, the anti-apoptotic caspase 9a rnRNA is expressed. 
Role of Ceramide in Apoptosis 
The bioactive sphingolipid, ceramide, is an important regulator of various stress 
responses, apoptosis, and cellular senescence, and the formation of ceramide from the 
hydrolysis of sphingomyelin or from de novo pathways has been observed in response to 
agonists such as tumor necrosis factor-a, y-interferon, 25-dihydroxyvitamin D3, 
interleukin- 1, ultraviolet light, heat, chemotherapeutic agents, fatty-acid synthase antigen, 
and nerve growth factor. When these agonists have induced the formation of ceramide, 
there are several targets of ceramide that are inducers of apoptosis as shown in figure 3. 
These targets include ceramide activated protein kinase (CAPK), cathepsin D, and 
serinelthreonine protein phosphatases PP1 (protein phosphatase 1) and PP2A (protein 
phosphatase 2A) also known as ceramide activated protein phosphatases (CAPPs) (3). 
Direct Targets of Ceramide 
The prominent role of ceramide as a regulator of cellular mechanisms necessitated 
the identification of these direct target enzymes previously mentioned. Cathepsin D has 
been shown to play an important role in proteolysis as well as apoptosis. Heinrich et al. 
found that cathepsin D is a direct target for ceramide and interaction with ceramide was 
necessary to cleave pro-cathepsin D into active cathepsin D (3). Studies by Kagedal et al. 
have shown that active cathepsin D, in response to oxidative stress, translocates from the 
lysosome and that activation of caspase 3 is dependent on this activation and translocation 
(4). It has been found that PKC-zeta (protein kinase C zeta) interacts directly with 
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ceramide thereby modulating the response to TNF (15). The resulting activation of PKC- 
zeta leads to the enhancement of splicing by increasing phosphorylation of hnRNPAl 
leading to nuclear translocation and increased RNA binding affinity (16, 17). Kolesnick et 
al. have reported on a ceramide-activated protein kinase (CAPK) in A-431 human 
epidermal carcinoma cells and HL-60 human promyelocytic leukemia cells, but the 
specificity of ceramide activation of CAPK, nor its role in intracellular signaling, have 
been defined (5). Ceramide-activated protein phosphatase (CAPP), belongs to the family of 
serinelthreonine protein phosphatases (6). CAPP was activated by ceramides that carried 
different lengths of N-linked fatty acyl groups and was not activated by sphingomyelin, 
sphingosine, or dihydroceramide (6). Also, CAPP activation in vitro closely matches the 
specificity of various cellular activities of ceramide, including apoptosis (6). Ceramide- 
induced apoptosis is inhibited by okadaic acid, an inhibitor of serinelthreonine protein 
phosphatases, which is additional evidence for a role of CAPP in mediating ceramide 
responsiveness (6). There are two types of ceramide-activated protein phosphatases, which 
inclde the serinelthreonine -specific protein phosphatases PPl and PP2A (7). Both PP2A 
and PP1 have been reported to be targets for natural ceramides in vitro and in vivo (7). 
Alternath 
Splicing (e.g. Caspase 9) 
Apoptosis 
Figure 3. Overview of the role of ceramide in apoptosis. several 
putative and direct targets of ceramide action have been identified. Of these, those that couple ceramide 
generation with downstream inducers of apoptosis include: ceramide activated protein kinase (CAPK), 
cathepsin D, and serinelthreonine protein phosphatases PP1 (protein phosphatase l) ,  PP2A (protein 
phosphatase 2A), and PKC (protein kinase C) (3). 
Ceramide Metabolism 
Formation of ceramide from the agonist induced hydrolysis of sphingomyelin (8) 
was shown in HL-60 human promyelotic leukemia cells treated with ercalcitriol. This and 
other agonists that serve to induce the hydrolysis of sphingomyelin suggests that a 
common theme of this group of agonists is associated with their different effects on growth 
suppression (6). In different cell systems, the ceramide formed downstream from these 
agonists induces either cell differentiation, cell-cycle arrest, apoptosis or cell senescence, 
and this suggests a role for ceran~ide in growth arrest and suppression (6). 
The de novo pathway of ceramide synthesis has emerged as being responsive to 
agonist stimulation (6) with ceramide generated by this pathway capable of exerting 
biological actions (6). As shown in figure 4, condensation of serine and palmitoyl CoA by 
serine palmitoyltransferase (SPT) initiates the pathway and generates ketosphinganine 
which is then reduced, N-acylated, and desaturated by addition of the 4-5 trans double 
bond in a series of enzymatic steps, leading to the generation of ceramide (6). Ceramide 
can also be synthesized by ceramide synthase acting on sphingosine, and the reverse step, 
the synthesis of sphingosine can be accomplished by ceramidases acting on ceramide. In 
addition ceramide can be synthesized from sphingomyelin using sphingomyelinase and the 
reverse can be accomplished using sphingomyelin synthase. 
Serine + Pnlmitoyl-CoA 
1 SERlNE PALMITOYL TRANSERASE 
3 Kemphinganine 
4 Sphinganine + Fatty Acid CoA 
C Dihydroceramide 
DIHYDROCERAMTDB Sphingmine 1 SIP 1- Phosphate CERAMDE PHOSHATAS 
mmi& W A S E  e E R k W E  
l-F%~pha~ CERAM..DE - 1 -P i SYNTHASE + $ f > h i n g x b  2 S P H  KINASE 
PHbSPFiATASE 16:o CERAMIDASE 
Figure 4. Overview of Ceramide Metabolism (3) 
The Role Of SR Proteins In Splicing 
SR proteins are a family of argininelserine rich domain containing proteins with 
both roles in constitutive RNA splicing and as regulators of alternative pre-mRNA 
processing (9). Spliceosome assembly requires many non-snRNP protein factors including 
members of the SR protein family (10). Each SR protein contains one or two N-terminal 
RNP-type RNA binding domains (RBDs) and a C-terminal domain enriched in Arg-Ser 
dipeptide repeats (RS domain) (lo), and SR proteins were shown to function in pre-mRNA 
splicing as both general and alternative splicing factors (10). In splicing deficient HeLa 
extracts, they were found to allow the splicing of several different pre-mRNAs (lo), and in 
another case, SR proteins were shown to modulate alternative splicing by affecting the 
usage of competing 5' or 3' splice sites in a concentration dependent manner (10). SR 
proteins are also required for the activity of splicing enhancer elements, which are RNA 
sequences, most frequently found in exons that are needed to activate certain weak splice 
sites (10). Specifically, the SR proteins, SRp30a and SRp30b have been shown to interact 
with U1 snRNP-specific 70K protein (U1 70k), and the RS domains of both proteins are 
required for this interaction (10). SRp30a has also been shown to bind 5' splice sites (10). 
These protein-protein and protein-RNA interactions have the potential to bring the two 
splice sites together across either the intron or the exon (10) and as splicing activators, SR 
proteins bind specific sequences in RNA enhancers and form complexes with other 
proteins (6). SR proteins are phosphorylated extensively in vivo and phosphorylation takes 
place mainly on serine residues within the RS domain (10). Addition of the serine 
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threonine phosphatase, PP1, to nuclear extract inhibits spliceosome assembly and 
phosphorylation of SR proteins is required in the progression of A con~plex to B complex 
of the spliceosome (10). Furthermore, alternative 5' splice selection is also affected (18). 
Dephosphorylation of SR Proteins and alternative splicing of caspase 9 
In addition, the generation of endogenous ceramide and PP1 activation was also 
shown to mediate the alternative splicing of an apoptotic factor, caspase 9, in a manner that 
promotes apoptosis. Ceramide treatment resulted in a decrease in the processing and 
expression of the pro-survival caspase 9b isoform of caspase 9 with a concomitant increase 
in the pro-apoptotic caspase 9a isoform. This effect required the generation of endogenous 
ceramide through the de novo pathway, and more importantly, inhibitors of protein 
phosphatase-1 abolished the ability of ceramide to affect the alternative splicing of caspase 
9. A hypothesis linking de novo ceramide synthesis to the alternative splicing of caspase 9 
is shown in figure 5. Interestingly, it has been found that increased expression of caspase 
9a due to de novo ceramide production occurred in PP1-dependent manner. Thus, both the 
phospho-state of SR proteins and the alternative splicing of caspase 9 are regulated by the 
generation of de novo ceramide and subsequent PP1 activation. These data suggest that 
alternative splicing may be an important mechanism for the regulation of apoptosis by 
ceramide. 
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The involvement of PP1 and endogenous ceramide in the dephosphorylation of SR 
proteins and the effects on caspase 9 alternative splicing suggested that at least one SR 
protein isoform was involved in this pathway. Previous studies using siRNA to SRp30a, in 
A549 lung adenocarcinoma cells showed that SRp30a is a major regulator in the 
alternative splicing of caspase 9 as shown in figure 6. A549 lung adenocarcinoma cells 
were treated with 200 nM siSRp30a and western blot analysis revealed an approximate 
85% downregulation of SRp30a (figure 6). RT-PCR analysis revealed a dramatic decrease 
in the caspase 9alcaspase 9b ratio. In these studies, we identified five possible purine-rich 
RNA sequences within the caspase 9 gene that correspond to the binding sites of SRp30a, 
and function as RNA cis-elements in the alternative splicing of caspase 9. 
Chemotherapy Increase in de novo ceramide 
. 
. 
n Caspase 9a 
Figure 5. Hypothesis of the signal transduction pathway 
mediating the alternative splicing of caspase 9. Chemotherapeutics act on ~ 5 4 9  
cells leading to de novo ceramide synthesis. This in turn leads to the activation of protein phosphatase 1 (PP l), 
which dephosphorylates SR proteins. Dephosphorylated SRp30a, an SR protein family member, binds to 
purine-rich cis-elements of the exon 3 ,4 ,  5, 6 cassette of caspase 9 pre-mRNA in order to regulate inclusion and 
exclusion of that cassette and favoring the caspase 9a splice variant. 
CON SRp3On siRNA 
I  
Figure 6. RNAi used to down regulate SRp30a. RNAi technology was used 
to downregulate SRp30a. A549 lung adenocarcinoma cells were treated with 200 nM siSRp30a, and 
Western blot analysis revealed an approximate 85% downregulation of SRp30a (right panel). RT-PCR 
analysis revealed a dramatic change in the caspase 9dcaspase 9b ratio (left panel). These studies were 
performed bfiutumn Massiello of the Chalfant laboratory. 
CHAPTER 2 Materials and Methods 
Cell Culture: A549 lung adenocarcinoma cells were purchased from American 
Type Tissue Culture Collection (http://www.atcc.org). These A549 cells were grown in 
50% RPMI 1640 (Invitrogen) and 50% DMEM (Invitrogen) supplemented with L- 
glutamine, 10% (vlv) fetal bovine serum (Invitrogen), 100 U/ml of penicillin G sodium 
(Invitrogen), and 100 pglml of streptomycin sulfate (Invitrogen). Cells were maintained at 
less than 80% confluency under standard incubator conditions (humidified atmosphere, 
95% air, 5% COz, 37" C). 
Electromobility Shift Assay: The following sequences were used for FITC-tagged RNA 
oligonucleotides: In Exon 3: r(5'Fl- gagaguuugaggggaaau), Between Exon 4 and Exon 5: 
r(5'Fl- uggaggaccaugggagguaggac) and in Exon 6: r(5'Fl- ugggagggaagcccaagcu). The 
following sequences were used for RNA oligonucleotide competitors without fluorescein: 
In Exon 3: r(5'-ugaggggaaau), Between Exon 4 and Exon 5: r(5'- augggaggua) and in 
Exon 6: r(5'- ugggagggaagc). RNA binding reactions were performed in a final volume of 
25 p1 containing: 100 ng of fluorescein-oligonucleotide, 50 pg nuclear protein extract or 50 
pg of recombinant SRp30a (generously provided by Dr.Adrian Krainer, Cold Harbor 
Springs Laboratory, New York), 40 U RNASIN, and 11.3 pg tRNAs in buffer composed 
of 50 mM HEPES, 5 mM DTT, 625 mM KC1, 5 mM DTT, 5 mM EDTA, and 0.125% 
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NP40. The reaction mixtures were incubated at 25' C for 30 minutes and then crosslinked 
with ultraviolet light for 30 minutes. Half of these samples were loaded on a 5% TBE 
CriterionTM Precast Gel (BioRad) for electrophoretic separation of RNA-protein(s) 
complexes for 1.5 hours at 115 volts at 4' C. The gel was then scanned using Molecular 
Imager@ FX (BioRad) with a 488nm EX (530 nm BP) laser. The Molecular Imager@ FX 
(BioRad), performs densitometry analysis and reveals differences in a given scan only 
within the linear range of statistical significance. An equal volume of 2 x Laemmli buffer 
(50 mM Tris-HC1, pH 6.8, 2% SDS, 10% glycerol, 0.04% bromophenol blue, and 250 mM 
p-mercaptoethanol) was added to the other half of the samples which were boiled for 10 
minutes. These samples were run on a 10% Tris-HCL CriterionTM Precast Gel (BioRad) for 
electrophoretic separation of RNA-protein(s) complexes for 1.5 hours at 50 volts through 
the stacking gel and then at 100 volts at 25' C. For supershift reactions, antibody to 
SRp30a (provided by Dr. Adrian Krainer, Cold Harbor Springs Laboratory, New York 
(1 : 10 diluted)) or non-specific IgG (1 mg/mL and 1 : 10 diluted (Sigma)) was added 20 min 
after addition of the oligonucleotide with an additional 30 min of binding time at 4' C. 
Samples were then subjected to electrophoretic separation and analyzed as described 
above. 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) Assay: Total RNA from 
A549 cells was isolated using the RNeasy kit (Qiagen) per manufacturer's protocol. This 
kit allows the investigator to lyse cells and remove all cellular components including 
lipids, proteins, and DNA and purify only RNA. This is done in an RNase free 
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environment. 1 pg of A549 total RNA was reverse transcribed using Superscript I1 reverse 
transcriptase (Invitrogen) and oligo(dT) as the priming agent. After 50 min incubation at 
42 "C, the reactions were stopped by 70" C heating for 15 min. Template RNA was then 
removed using RNase H (Invitrogen). 
For evaluating the expression of caspase 9 splice variants derived from the minigene, an 
upstream vector 5' primer to caspase 9 (5' TCACTATAGGGAGACCCAAGC) and a 3' 
primer E7A (5' AAGATGTCACTGGGTGTGGGCAAACTAGA) (Genosys, Inc.) were 
used. Using these primers, 20% of the reverse transcriptase reaction was amplified for 
35 cycles (94" C, 30s melt; 63" C, 30 s anneal; 72" C, 1 min extension) using Platinum Tag 
DNA polymerase (Invitrogen). The RT-PCR reaction was examined by 1.5% agarose gel 
electrophoresis and scanned on a Molecular Imager@ FX (BioRad). The Molecular 
Imager@ FX (BioRad), performs densitometry analysis and reveals differences in a given 
scan only within the linear range of statistical significance. 
Nuclear Extracts: Nuclear extracts were prepared from A549 lung adenocarcinoma cells 
according to the method of Dignam et al. (11) by Autumn Massiello. Protein 
concentrations were determined by a modification of the Bradford method using the Bio- 
Rad protein assay reagent (Bio-Rad). 
Protein Extraction: Cells were lysed with 0.1 mL of 2 x Laemmli buffer (50 mM Tris-HC1, 
pH 6.8, 2% SDS, 10% glycerol, 0.04% bromophenol blue, and 250 mM p-mercaptoethanol) 
after resuspension in 0.1 mL of ice-cold phosphate-buffered saline (PBS). Samples were 
18 
boiled for 10 min and either examined directly by 10% SDS-polyacrylamide gel 
electrophoresis or stored at -20' C. 
Western Immunoblotting: Total protein lysate (20 pg) was subjected to 10% SDS-PAGE. 
Proteins were transferred to polyvinylidene difluoride membrane (Bio-Rad) and blocked in 
5% milk, 1 x PBS-T (M-PBS-T) for 2 h. The membrane was incubated with anti-SRp30a 
(provided by Dr. Adrian Krainer, Cold Harbor Springs Laboratory, New York (1:100 
diluted)) or anti-a-tubulin (Santa Cruz Biotechnology (1:2000 diluted)) for 2 h in M-PBS- 
T followed by 3 washes with PBS-T. The membrane was then incubated with a secondary 
antibody of horseradish peroxidase-conjugated goat anti-rabbit IgG antibody (anti- 
SRp3Oa) or horseradish peroxidase-conjugated anti-mouse IgM (Cal-Biochem) (anti-a- 
tubulin) for 45 min followed by 3 washes with PBS-T. Immunoblots were developed using 
Pierce ECL reagents and Bio-Max film. 
Replacement Mutagenesis: The caspase 9 minigene was cloned into the vector 
pcDNA3.1(-) Zeocin purchased from Invitrogen. The five sequences selected for 
replacement mutagenesis are shown in figure 7. To mutate these purine-rich sequences in 
Exon 3, between Exons 4 & 5, between Exons 5 & 6, Exon 6, and Exon 6 & 7, the 
Quikchange I1 XL Site-Directed Mutagenesis Kit by Stratagene was used. This kit enables 
the investigator to introduce mutations into a cloned gene by several techniques. First, the 
kit provides instructions on primer design with regards to % mismatch, length, and GC 
content. Secondly, it provides the reagents for mutant strand synthesis, digestion of 
parental strand, and the subsequent transformation of bacterial cells. To mutate the selected 
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purine-rich sequences in the caspase 9 minigene and for efficient screening of mutants, 
these purine-rich sequences were mutated to Hind I11 sites. The mutagenesis primers used 
for the Exon 3 mutant are 5' 
CAGGTGCTCTTGAGAGTTTGAAGCTTGATGCAGATTTGGTGAG 3' and 
3'GTCCACGAGAACTCTCAAACTTCGAACTACGTCTAAACCACTC 5'. The 
mutagenesis primers used for the Exon 4 and 5 mutant are 5' 
GCCCTTACATCTGGAGGACCATAAGCTTTAGGACGGCCCAGCGGC 3' and 3' 
CGGGAATGTAGACCTCCTGGTATTCGAAATCCTGCCGGGTCGCCG 5'. The 
mutagenesis primers used for Exon 5 and 6 mutant are 5' 
CTGGGAGAAGCCCTCTGGGAGAAGCTTTGCAGAGACCAGGTCTGC 3' and 3' 
GACCCTCTTCGGGAGACCCTCTTCGAAACGTCTCTGGTCCAGACG 5'. The 
mutagenesis primers used for the Exon 6 mutant are 5' 
CCAGCTGCCCCAGCCTGGGAAGCTTTCCCAAGCTCTTTTTCATCC 3' and 3' 
GGTCGACGGGGTCGGACCCTTCGAAAGGGTTCGAGAAAAAGTAGG 5'. The 
mutagenesis primers used for the Exon 6 and 7 mutant are 5' 
GGGTGGGTCTGGTGGGGAAGCTTCCGCCACCTGCTTC 3' and 3' 
CCCACCCAGACCACCCCTTCGAAGGCGGTGGACGAAG 5'. The resulting plasmids 
were purified to be endotoxin free using the services of the Molecular Biology Core 
Facility of the Massey Cancer Center of Virginia Commonwealth University. 
Sequence 
1 ......... 
2 ......... 
I 
Location 
Exon 3 (1 8,333-1 8,339 bp) 
Bnv Exons 4&5 (1 9,441 -19,446 bp) 
Bnv Exons 5&6 (20472 - 20478 bp) 
Exon 6 (21,582-21,588 bp) 
Bnu Exon 6&7 (21648-21653 bp) 
Figure 7. The five purine-rich sequences of capase 9 pre-mRNA 
to undergo replacement mutagenesis. 
Sequence VerlJication of Minigene Splice Variants: In order to ensure that the sequences of 
the splice variants of the caspase 9 minigene correspond to  the actual sequences of the 
caspase 9a and 9b splice variants minus Exon 1, Exons 8, and Exon 9, the cloned caspase 9 
minigene (figure 8) was transfected into A549 lung adenocarcinoma cells. After 24 hours, 
RNA was isolated from the cells using Qiagen's RNeasy Mini Kit (described previously). 
RT-PCR was performed as outlined above. Once the PCR reactions were examined by 
1.5% agarose gel electrophoresis, bands on the gel suspected of being the caspase 9a 
variant and the caspase 9b variant were removed from the gel, and the RT-PCR products 
were isolated using the Qiagen MinElute Gel Extraction Kit. This kit allows the 
investigator to isolate DNA from an agarose gel by dissolving the agarose and eluting it on 
a column followed by the elution of purified DNA. These RT-PCR products were sent to 
SeqWright DNA Technology Services to be sequenced and their sequences were verified 
by checking their exon sequences against the NCBI database found at 
http://www.ncbi.nlm.nih.gov/. 
1. Step 1: High Fidelity PCR of the Genomic Gene Pieces of Caspase 9 
2. High Fidelity PCR of Caspase 9 PCR fragments with Restriction Sites. 
Step 2 
EcoRV -Im H h d  Ill 
Figure 8. Structure and cloning of the caspase 9 minigene. 1) 
The caspase 9 minigene was constructed by amplifying selected gene pieces of the caspase 9 
gene using genomic DNA. This resulted in a caspase 9 minigene that excluded exon 1, exon 8, 
and exon 9. 2) Restriction sites were then engineered into the caspase 9 minigene so that when 
the caspase 9 minigene was digested with the corresponding restriction enzymes and the vector 
used for cloning (pcDNA3.1/(-) Zeocin) was digested with these same enzymes, the caspase 9 
minigene could be cloned into this vector and subsequently used for transfections. 
CHAPTER 3 Results 
Caspase 9 Minigene producing splice ratio similar to that of endogenous 
caspase 9 
Previously, a minigene plasmid to examine the alternative splicing of caspase 9 in 
cells was constructed (figure 8). To examine whether this construct behaved in a similar 
manner as the endogenous gene, the plasmid was transiently transfected into A549 cells. 
Using an RT-PCR based assay that examines only the minigene produced RNA, the ratio 
of minigene caspase 9a19b was determined to be 3.0, comparable to the endogenous ratio 
of 2.0. The resulting RT-PCR products were visualized using agarose gel electrophoresis 
(figure 9). 
100 BP ladder 
v RT-PCR for C9 minigene 
Figure 9. Transfection of A549s with the caspase 9 minigene 
(N=3). After transfection with the caspase 9 minigene, the wild type rninigene produced the 
caspase 9a (910 BP) and caspase 9b (446 BP) splice variants in a ratio (approximately 3: l)  
analogous to that of the endogenous wild type caspase 9 gene (approximately 2: 1). These caspase 9 
rninigene products were cloned into a TOP0 vector and sequence verified. 
Caspase 9a Minigene Sequence Verification 
NNNNNNNNNNNNNNNNNNGTANNGTTTTGTAATAAAAAAACCTATAAATATTCCGGATTATTCATACCGTCCCACCATC 
GGGCGTGCTAGCGGATCCGAGCTCGAGATCTGCAGCTGGTACCCGGGTCTAGAATTGCCCTTTCACTATAGGGAGA 
CCCAAGCTGGCTAGCGTTTAAACGGGCCCTCTAGACTCGAGGGAGTCAGGCTCTTCCTTTGTTCATCTCCTGCTTAGA 
GGACACAGGCCAGGACATGCTGGCTTCGTTTCTGCGAACTAACAGGCAAGCAGCAAAGTTGTCGAAGCCAACCCTAG 
AAAACCTTACCCCAGTGGTGCTCAGACCAGAGATTCGCAAACCAGAGGTTCTCAGACCGGAAACACCCAGACCAGTG 
GACATTGGTTCTGGAGGATTCGGTGATGTCGGTGCTCTTGAGAGTTTGAGGGGAAATGCAGATTTGGCTTACATCCT 
GAGCATGGAGCCCTGTGGCCACTGCCTCATTATCAACAATGTGAACTTCTG,CCGTGAGTCCGGGCTCCGCACCCGCA 
CTGGCTCCAACATCGACTGTGAGAAGTTGCGGCGTCGCTTCTCCTCGCTGCATTTCATGGTGGAGGTGAAGGGCGAC 
CTGACTGCCAAGAAAATGGTGCTGGCTTTGCTGGAGCTGGCGCGGCAGGACCACGGTGCTCTGGACTGCTGCGTGG 
TGGTCATTCTCTCTCACGGCTGTCAGGCCAGCCACCTGCAGTTCCCAGGGGCTGTCTACGGCACAGATGGATGCCCT 
GTGTCGGTCGAGAAGATTGTGAACATCTTCNATGGGACCAGCTGCCCCAGCCTGGGANGGAAGCCCAAGCTCTTTTT 
CATCCAGGCCTGTGGTGGGGAGCAGAAAGACCATGGGTTTGAGGTGGCCTCCNCTTCCCCTGAAGANNANTCCCCT 
NGNAGTAACCCCNANCCANATGCCACCCCGTTCCAGGANNNTTTGAGGANCTTCGACCAGCTGGACGCCNTATCTAG 
TTTGNCNCN 
Caspase 9b Minigene Sequence Verification 
ANNNNNNNNNNNNNNNNNNTTCGTNNNNGTTTTGTAATAAAAAAACCTATAAATATTCCGGATTATTCATACCGTCCCA 
CCATCGGGCGTGCTAGCGGATCCGAGCTCGAGATCTGCAGCTGGTACCCGGGTCTAGAATTGCCCTTTCACTATAGG 
GAGACCCAAGCTGGCTAGCGTTTAAACGGGCCCTCTAGACTCGAGGGAGTCAGGCTCTTCCTTTGTTCATCTCCTGC 
TTAGAGGACACAGGCCAGGACATGCTGGCTTCGTTTCTGCGAACTAACAGGCAAGCAGCAAAGTTGTTGTCGAAGCCAAC 
CCTAGAAAACCTTACCCCAGTGGTGCTCAGACCAGAGATTCGCAAACCAGAGGTTCTCAGACCGGAAACACCCAGAC 
CAGTGGACATTGGTTCTGGAGGATTCGGTGATGTCGAGCAGAAAGACCATGGGTTTGAGGTGGCCTCCACTTCCCCT 
GAAGACGAGTCCCCTGGCAGTAACCCCGAGCCAGATGCCACCCCGTTCCAGGAAGGTTTGAGGACCTTCGACCAGC 
TGGACGCCATATCTAGTTTGCCCACACCCAGTGACATCTTAAGGGCAATTCGAAGCTTAGGCCTGGTAAGCCTATCCC 
TAACCCTCTCCTCGGTCTCGATTCTACGCGTACCGGTCATCATCACCATCACCATTGACGTCTCTAGCTTGGAGTCGA 
CAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACT 
GCATTCTAGTTGTGGTTNGTCCAAACTCATCAATGTATCTTATCATCTCTCGACTCTGCTGAAGAGGAGGAAATTCTCC 
TTGAAGTTTCCCTGGTGTTCAAAGTTTGCACCANACGCANCTCTGTTCACTGGTCCGGCGTATTAAAACA 
CGATACATTGTTATTAGTACATTTATTAAGCGCTAGATTCTGTGCGTTGTNGANTTACAGAN 
Figure 10. Sequence Verification of the caspase 9 splice variants 
produced by the caspase 9 minigene. Shown above are the sequences of the 
isolated RT-PCR products of caspase 9a and 9b. After obtaining the these sequences, they were 
verified using the NCBI database as the exact sequences of the endogenous caspase 9a splice 
variant and caspase 9b variant minus exons 1, 8, and 9 and containing the expected pcDNA3. I(-) 
Zeocin sequence. 
Sequence Verification of the caspase 9 splice variants produced by the caspase 9 
minigene 
The PCR products of the splice variants caspase 9a and caspase 9b shown in figure 
9 were removed from the agarose gel, cloned into a pBlueBac4.5IV5-His-TOP0 vector 
from Invitrogen, and sequenced using SeqWright DNA Technology Services. Figure 10 
shows that the caspase 9 splice variants produced by the caspase 9 minigene are the exact 
sequences of the endogenous caspase 9a splice variant and caspase 9b variant minus exons 
1, 8, and 9 and containing the expected pcDNA3.1(-) Zeocin sequence. 
Replacement Mutagenesis of Sequences 1 ,2 ,  and 4 alters the splice ratio of caspase 9a 
and 9b 
Replacement mutagenesis was performed on five purine-rich sequences (Sequences 
1-5 shown in figure 7) in the caspase 9 minigene as outlined in the Materials and Methods 
section. Of these five sequences, three of them, when mutated, affected the splice ratio of 
caspase 9a and caspase 9b. Visualized in figure 11 are the RT-PCR products from A549 
cells transfected with caspase 9 minigene with two different mutations introduced into 
sequences 2 and 4. The mutation of these sequences corresponding to the purine-rich 
sequence between Exons 4 and 5 and the purine-rich sequence in Exon 6, induced a 
decrease in the splice ratio of caspase 9alcaspase 9b. Therefore, when both sequences 2 
and 4 are mutated, a decrease in the splice ratio of caspase 9alcaspase 9b is observed. 
Visualized in figure 12 are the RT-PCR products from A549 cells transfected with 
caspase 9 minigene with sequence 1 mutated. Mutating this sequence increased the splice 
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ratio of caspase 9dcaspase 9b. Since this mutation results in an increase of the caspase 
9dcaspase9b ratio, this purine-rich sequence in Exon 3 acts as a repressor element. 
Mutagenesis of sequences 3 and 5 had no effect on the ratio of caspase 9dcaspase 9b. 
+ Caspase9a 
i 
+- Caspasc 9b 
s 
Figure 11. Purine-Rich RNA Cis-Elements #2 and #4 Affect the 
Alternative Splicing of Caspase 9 Pre-mRNA (N=6). I =  loo BP ladder, 
2= Vector Control, 3= Wild Type Caspase 9 Minigene, 4= E6 Mutant 4 minigene, 5= E4 and E5 
Mutant 2 minigene. These two mutants shift the direction of the splice ratio toward caspase 9b. 
Figure 12. Purine-Rich RNA Cis-Element #1 Acts As A 
Repressor Element for the Caspase 9a Splice Variant (N=6). I=  
100 BP ladder, 2= Vector Control, 3= Wild Type C9 Minigene, 4= E3 Mutant 1 minigene. After 
mutating this purine-rich sequence in exon 3 the splice ratio shifts in the direction of caspase 9a 
indicating that it acts as a repressor element. 
RNAIProtein Binding Studies Using Electromobility Shifts and SDS PAGE 
After the replacement mutagenesis on the five purine-rich sequences 
yielded three sequences that were possible sites for binding RNA splicing factors, 
fluorescein-tagged oligonucleotides corresponding to these three sequences were used in 
electromobility shift assays and SDS-PAGE assays. Since the purine-rich sequence in 
Exon 3 was a possible repressor element in caspase 9 pre-mRNA, the corresponding 
fluorescein tagged oligonucleotide and its competitive inhibitor were used in EMSA assays 
to examine if this oligonucleotide bound proteins from nuclear extracts, which are rich in 
transcription factors and splicing factors. The EMSA competitor study in figure 13 showed 
that the fluorescein-tagged exon 3 sequence bound RNA trans-factors and is effectively 
inhibited by the addition of an unlabeled oligonucleotide corresponding to the purine-rich 
exon 3. Thus, this sequence is a possible candidate for the binding of a repressor protein. 
Those assays were repeated and subjected to SDS-PAGE analysis for determination 
of the specific protein (or protein complex) size bound to the RNA sequence as shown in 
figure 14. The RNA oligonucleotides used for this assay correspond to the purine-rich 
sequences in sequence 1 and sequence 4. These results demonstrate the specific binding of 
-66, 56, 45, 38 kDa proteins to the oligonucleotide sequence in exon 3 and an -66 kDa 
protein(s) bound to the exon 6 RNA oligonucleotide sequence. 
Exon 3 RNA Oligo 
Figure 13. EMSA Competitor Studies for Sequence l(Exon 3) 
Using A549 Nuclear Extracts (N=3). Lane 1- EMSA as described previously, 
including nonspecific competitor oligo- gaauucgcacguua. Lane 2- EMSA as described previously, 
including specific competitor oligo for exon 3 - ugggagggaagcc. The competition away in lane 2 
shows that the purine-rich sequence in exon 3 binds proteins in the A549 nuclear extract. 
Figure 14. SDS-PAGE Analysis To Determine Sizes of Protein 
Complexes bound to RNA sequences (N=3). NSC= Nonspecific 
Competitor and SC= Specific Competitor. These results demonstrate the specific binding of -66, 
56,45,38 kDa proteins to the oligonucleotide sequence in exon 3 (possible repressor element). 
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Because the mutation in sequence 2 (Intron 4-5) shifted the ratio of the splice variants 
in the direction of caspase 9b, the EMSA competitor studies and SDS-PAGE was repeated 
using a fluorescein-tagged oligonucleotide corresponding to that sequence. In figure 15, 
the EMSA and SDS-PAGE competitor studies showed that fluorescein-tagged 
oligonucleotides corresponding to the purine-rich sequences in sequence 4 and sequence 2 
bind specifically to RNA trans-factors. This was confirmed by competition studies. Thus, 
sequence 2 binds trans-factors of sizes 66, 56, and 38 Kd, and sequence 4 also binds trans- 
factor complexes of 66, 56, and 38 kD in size. 
We hypothesized that SRp30a might bind sequence 2 and sequence 4 given that the 
literature shows SRp30a having a strong affinity for purine-rich sequences. Thus, it was 
important to establish whether or not SRp30a interacts with these sequences. Recombinant 
SRp30a was obtained from a collaborating lab, and these EMSAs were repeated using this 
recombinant SRp30a. As seen in figure 16, when the EMSA was repeated using 
recombinant SRp30a, sequences 2 and 4 bound to SRp30a, indicating that these sequences 
have a strong affinity for SRp30a. 
Figure 16. EMSA Competitor Studies For Sequence 2 and 4 
(Intron 4-5 and Exon 6) Using Recombinant SRp30a (N=3). I=  
Control (IgG), 2= Intron 4-5 Oligo, 3= Exon 6 Oligo. In the control lane, there is no shift evident. 
In lanes 2 and 3, a clear shift can be seen when recombinant SRp30a is used which shows the 
strong affinity of SRp30a for these two purine-rich sequences, (These experiments were conducted 
in colaboration with Autumn Massiello of the Chalfant laboratory). 
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Additional confirmation that SRp30a bound to these sequences was done by 
repeating the EMSA using both A549 nuclear extracts and recombinant SRp30a and the 
inclusion of an antibody specific to SRp30a. In figure 17, addition of an antibody specific 
to SRp30a induced a "supershift" with a concommitant decrease of SRp30alsequence 4 
complex. This confirmed that SRp30a bound to these two purine-rich sequences that 
regulate the inclusion of the exon 3,4,5,6 cassette of the caspase 9 gene. 
Loss 
of sldft 
Figure 17. EMSA Supershift for Sequence 4 (Exon 6 oligo) 
(N=3). The first two lanes are EMSAs using recombinant SRp30a and the last two lanes are 
EMSAs using A549 nuclear extracts. Non-specific IgG antibody is used as a control for these 
EMSAs, and IgG antibody specific to SRp30a is used to create both loss of shift and a supershift 
indicating that SRp30a does bind to this purine-rich sequence (These experiments were conducted 
in collaboration with Autumn Massiello of the Chalfant laboratory 
Chapter 4 Discussion 
Previously, our laboratory showed that siRNA to SRp30a changed the splice ratio 
of caspase 9al9b showing a decrease in caspase 9a expression with a concon~itant increase 
in caspsase 9b expression. In this study, we showed that mutation of the purine-rich 
sequences 2 and 4 (Intron 4-5 and Exon 6 of the caspase 9 gene) induced a decrease in the 
splicing ratio of caspase 9alcaspase 9b. This finding demonstrated that these RNA cis- 
elements are required for the inclusion of the exon 3, 4, 5, 6 cassette and are exonic 
splicing enhancers. Furthermore, mutation of the purine-rich sequence in exon 3 induced 
an increase in the caspase 9alcaspase 9b ratio acting as a repressor RNA cis-element. Both 
exonic enhancers specifically bound RNA splicing factors, specifically SRp30a. These 
findings are important for several reasons. First, the alternative splicing mechanism of 
caspase 9 splicing is better defined. Second, these findings demonstrate a link between SR 
proteins and the alternative splicing of caspase 9. Finally, these findings have direct 
relevance to mechanisms governing the sensitization of cancer cells to chemotherapy. 
Liu et a1 previously reported that SRp30a had an affinity for the purine-rich 
sequences, RGAACAAC and AGGACRRAGC, based on SELEX binding studies where R 
represents a purine (12). In additional studies they performed, they found exon splicing 
enhancers (ESEs) with sequences, AGGAGGA, GACCCGG, CGCAGGG, CAGAGGU, 
and GAGACGA bound SRp30a with high affinity and greatly enhanced splicing (12). 
Furthermore, unpublished studies from our laboratory showed that siRNA against SRp30a 
decreased the splice ratio of caspase 9alcaspase 9b. Based on these findings, we proceeded 
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with replacement mutagenesis of five sites identified in caspase 9 pre-mRNA that are as 
uncharacteristically purine-rich as the aforementioned sequences. Indeed, mutating 
sequences 2 and 4 had a dramatic effect on the alternative splicing of caspase 9, reducing 
the ratio of caspase 9alcaspase 9b. Binding studies using oligonucleotides that correspond 
to these sequences demonstrated specific interaction of these sequences with RNA trans- 
factors. Our laboratory further showed that these sequences interacted specifically with 
SRp30a. This finding was important because it provided strong mechanistic evidence that 
SRp30a plays an important role in alternative splicing of caspase 9. Thus, for the first time, 
SRp30a was shown to be involved in regulating the inclusion of a large exon cassette as is 
the case for caspase 9 pre-mRNA. 
Given these findings, there are finally implications for a link between de novo 
ceramide synthesis and the dephosphorylation of SR proteins favoring to the caspase 9a 
phenotype. Although there is no current evidence directly linking dephosphorylation of SR 
proteins to the alternative splicing of caspase 9, the SR protein SRp30a, is now directly 
linked as an important regulator of this mechanism. As mentioned before, PP1 has been 
reported as a target for activation by natural ceramides in vitro (9), and SR proteins have 
been shown to be substrates of PP1 (9). Chalfant et a1 have reported that de novo ceramide 
synthesis increases the ratio of caspase 9alcaspase 9b and in their experiments, inhibitors 
to PP1 abolished this effect of ceramide on the splice ratio, thus showing that ceramide 
altered the splice ratio in a PPl dependent manner (13). Because our laboratory showed 
that siRNA against SRp30a decreased the splice ratio of caspase 9alcaspase 9b and SR 
40 
proteins are known substrates of PP 1, the accumulated indirect evidence strongly suggests 
a link between de novo ceramide synthesis and the dephosphorylation of SRp30a leading 
to an increase in the splice ratio of caspase 9alcaspase 9b. 
This leads us to a possible h h ~ r e  target for therapy in lung adenocarcinoma cells. If 
excessive phophorylation of SRp30a in the spliceosome leads to an anti-apoptotic(pro- 
cancer phenotype) then a possible target could be the kinase that phosphorylates SRp30a. 
Prasad et. a1 have reported that ClWSty (Clkl) is a protein kinase that when 
autophosphorylated, phosphorylates SR proteins (14). Which SR proteins get 
phosphorylated by ClWSty depends on the nature of the autophosphorylation that it 
undergoes. From their experiments, they have found that when ClWSty autophosphorylates 
on Tyr residues, but not SerIThr residues, the result is phosphorylation of SRp30a (14). 
Interestingly, they found that SC35 is phosphorylated when SerIThr residues are 
autophosphorylated by ClWSty, and that SRp40 is phosphorylated by ClWSty when no 
autophosphorylation takes place (14). It is evident that ClWSty is responsible for 
phosphorylating several different SR proteins depending on its autophosphorylation status, 
so this allows for different scenarios of targeted therapy. One possibility would be to treat 
cells with antibodies specific to ClWSty, which are tagged with catalytic residues that alter 
the tyrosine phosphorylation of ClWSty. This would be be a precise targeting of ClWSty 
that would allow it to hnction as a kinase for all its other substrates except for SRp30a. 
Perhaps this targeted therapy scheme seems too unrealistic, so a more reasonable approach 
to therapy would be to introduce to adenocarcinoma cells siRNA to ClWSty to 
4 1 
downregulate it, so that SRp30a would be less phosphorylated, and the catalytic activity of 
PP1 on SRp30a would be more effective in yielding the pro-apoptotic caspase 9a 
phenotype. Even this kind of treatment must be monitored very closely, because as 
mentioned before, ClklSty phophorylates other SR proteins as well including SRp40 and 
SC35. It is quite possible that excessive dephosphorylation of these SR proteins could have 
undesirable consequences. Lastly, since we have found that sequence 1 (in Exon 3) acts as 
repressor element, which when mutated, favors the pro-apoptotic phenotype, 
adenocarcinoma cells could be treated locally by transfecting them with a cloned full 
caspase 9 gene with a silent mutation introduced in this purine-rich repressor sequence. 
The silent mutation would allow for the coding of the same amino acids, but would not be 
purine-rich. In this way, we could shift the splice ratio in the direction of caspase 9a while 
still having a completely functional caspase 9a. 
So, preliminary studies have shown that siRNA to SRp30a decreased the splice 
ratio of caspase 9a19b. Furthermore, when the purine-rich binding sites for SRp30a in 
Intron 4-5 and Exon 6 of the caspase 9 gene are mutated, there is also a decrease in the 
splice ratio of caspase 9alcaspase 9b. Because of these findings we realize now that SR 
proteins, specifically SRp30a, are part of the mechanism of the alternative splicing of 
caspase 9 and that SRp30a fits into the cascade of de novo ceramide synthesis leading to 
the alternative splicing of caspase 9. Finally, these findings allow for the possibility of new 
types of chemotherapy to treat cancer. 
42 
Therefore in this study, we have identified two purine-rich sequences that act as 
exonic splicing enhancers for the inclusion of the exon 3, 4, 5, 6 cassette of caspase 9 pre- 
mRNA. The Chalfant laboratory demonstrated that these ESE's interact specifically with 
SRp30a. Therefore, the finding that SRp30a is part of the mechanism of the alternative 
splicing of caspase 9 pre-mRNA finally provides the critical link to PP1 and de novo 
ceramide synthesis. Lastly, these findings allow for the possibility of new types of 
chemotherapy to treat cancer as well as possible diagnostic applications. 
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